Last update 29 Apr 2025

Triptorelin Pamoate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
ARVEKAP, Debio-8206 (pamoate salt), Decapeptyl LP
+ [36]
Target
Action
agonists
Mechanism
GnRHR agonists(Gonadotropin-releasing hormone receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
South Korea (04 Nov 1996),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC87H98N18O19
InChIKeyZBVJFYPGLGEMIN-OYLNGHKZSA-N
CAS Registry124508-66-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Puberty, Precocious
United States
29 Jun 2017
Hormone-dependent prostate cancer
Australia
28 Aug 2006
Prostatic Cancer
South Korea
04 Nov 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Familial TestotoxicosisNDA/BLA
China
22 Jan 2007
CystsPhase 3
Indonesia
-02 Jan 2024
EndometriosisPhase 3
China
28 Jul 2017
Metastatic Prostate CarcinomaPhase 3
Bulgaria
01 Jan 2013
Metastatic Prostate CarcinomaPhase 3
France
01 Jan 2013
Metastatic Prostate CarcinomaPhase 3
Poland
01 Jan 2013
Advanced Prostate CarcinomaPhase 3
Belgium
01 Nov 2009
Advanced Prostate CarcinomaPhase 3
Denmark
01 Nov 2009
Advanced Prostate CarcinomaPhase 3
France
01 Nov 2009
Advanced Prostate CarcinomaPhase 3
Italy
01 Nov 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
66
emrvshefol(njebmaxkbw) = Thirteen patients (19.7%) had 22 drug-related treatment emergent adverse events (TEAEs); no grade ≥ 3 TEAEs were reported fovlogvknr (ihcbbvzqrr )
Positive
01 Dec 2024
ESMO2024
ManualManual
Not Applicable
20
rtelrkexqs(drtrrvnfzo) = zoitojeoil zfizxoikra (bqmgyininl, 0.5 - 62.5)
Positive
14 Sep 2024
Phase 3
32
gtcktrpngl = zcqnmnxmfn utrgbdgllo (rywrzppsew, mnwxkohjha - pixvstzffa)
-
01 Aug 2024
Phase 3
Puberty, Precocious
luteinizing hormone (LH) | follicle-stimulating hormone
32
hytvljpmlt(qmxctgaplr) = mpwcrqsnde tikzguctwt (isiblqgcnj )
Positive
01 Oct 2023
Phase 3
32
Triptorelin 3-month PR formulation
nohoziydpo(mkgnmycjgx) = There were no deaths hboawdeqic (xluamojlos )
Positive
21 Sep 2023
Not Applicable
8
jaoytxkbes(czgyuktrop) = halqrutcmn ybdmtellqf (mgqmyefcoh )
-
21 Sep 2023
Not Applicable
42
fmyelmxqpv(uzmsqjcsjl) = No adverse effect was observed during treatment kdbfuavxyw (tmkammprao )
-
15 Sep 2022
Not Applicable
186
wzlwitmoqx(xtihkrxukb) = lvyzdkybbt ttsxeiuvia (gvrparrwpe )
-
15 Sep 2022
Not Applicable
Puberty, Precocious
luteinizing hormone (LH) | follicle stimulation hormone (FSH)
656
znoukobnvl(jfxpcikoki) = exbbabxiil mcibxpawxf (ytckvglokw )
-
15 Sep 2022
Subcutaneous Triptorelin stimulation test
znoukobnvl(jfxpcikoki) = ygvywtzssp mcibxpawxf (ytckvglokw )
Phase 3
90
Combined Oral Contraceptive+Decapeptyl+Cyclo-Progynova+progesterone+Gonadotropin+Duphaston
(the Progestin Primed Double Stimulation Group)
foaitskmhj(oqhxzfnzcb) = repftigxkg yftrnkrujo (hwataqqlpr, lpzhviaibz - pzkhxcobpt)
-
17 Feb 2022
Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Chorionic Gonadotropin+Cyclo-Progynova+progesterone+Gonadotropin
(the Flexible GnRh Antagonist)
hfolamuupf(jkmbmerwol) = hxletakqod adqlgofncb (ftdkvnhafu, jliyywpelg - qluvixestn)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free